Conventional radiography and correlated factors of enthesopathies of the Achilles tendon and plantar fascia in patients with axial spondyloarthritis

Ebru Yılmaz; Özge Pasin; Loiane Cristina de Souza; Guilherme Torres Vilarino; Alexandro Andrade; Camila Gusmão Vicente de Carvalho; Barbara Bayeh; Fernando Henrique Carlos de Souza; Renata Miossi; Pleiades Tiharu Inaoka; Takashi Matsushita; Naoki Mugii; Samuel Katsuyuki Shinjo

doi:10.4081/reumatismo.2024.1709

Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

Search Results

##search.searchResults.foundPlural##

Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

G. Andrisani, E. Gremese, L. Guidi, A. Papa, M. Marzo, C. Felice, D. Pugliese, A. Armuzzi

75-78

27-05-2013

https://doi.org/10.4081/reumatismo.2013.75

2976

PDF: 913
Splenic tuberculosis in a patient with ankylosing spondylitis treated with adalimumab

V.F. Azevedo, E. Paiva, T. Tosin, A. Ferreira, A.M. Ferreira, M. Fernandes

171-174

09-11-2011

https://doi.org/10.4081/reumatismo.2011.171

1043

PDF: 782
Anti-TNF agents for the treatment of active non-radiographic axial spondyloarthritis

I. Olivieri, Salvatore D'Angelo, C. Palazzi, P. Leccese, A. Nigro, A. Padula

1-3

28-03-2013

https://doi.org/10.4081/reumatismo.2013.1

2294

PDF: 748
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs

F.M. Perrotta, O. Addimanda, R. Ramonda, S. D’Angelo, E. Lubrano, A. Marchesoni, I. Olivieri, L. Punzi, C. Salvarani, A. Spadaro

208-214

06-11-2014

https://doi.org/10.4081/reumatismo.2014.756

2673

PDF: 1475
A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes

Rodrigo Garcia-Salinas, Sebastian Magri, Alvaro Ruta, Santiago Ruta

08-05-2025

https://doi.org/10.4081/reumatismo.2025.1748

882

PDF: 245
Psoriatic arthritis: treatment strategies using biologic agents

S. D'Angelo, C. Palazzi, I. Olivieri

113-121

05-06-2012

https://doi.org/10.4081/reumatismo.2012.113

1276

PDF: 1182
Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco

19-12-2023

https://doi.org/10.4081/reumatismo.2023.1602

1828

PDF: 456
A short history of anti-rheumatic therapy - VII. Biological agents

G. Pasero, P. Marson, B. Gatto

185-194

09-11-2011

https://doi.org/10.4081/reumatismo.2011.185

1506

PDF: 1239
GISEA: an Italian biological agents registry in rheumatology

G. Lapadula, G. Ferraccioli, C. Ferri, L. Punzi, F. Trotta

155-164

09-11-2011

https://doi.org/10.4081/reumatismo.2011.155

2332

PDF: 1593
Approved indications and other possible utilizations of anti-TNFa biologic drugs

W. Grassi, C. Montecucco

30-33

https://doi.org/10.4081/reumatismo.2005.4s.30

1144

PDF: 895
Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report

Faiq Gorial, Nabaa Awadh, Ali Al-Shakarchi, Ghaith Al-Gburi

30-10-2024

https://doi.org/10.4081/reumatismo.2024.1678

1667

PDF: 292
Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

R. Scrivo, F. Conti, F.R. Spinelli, S. Truglia, L. Magrini, M. Di Franco, F. Ceccarelli, G. Valesini

107-117

https://doi.org/10.4081/reumatismo.2009.107

1911

PDF: 1161
Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases

G. Lapadula

22-29

https://doi.org/10.4081/reumatismo.2005.4s.22

789

PDF: 1085
Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

P. Sarzi- Puttini, M. Antivalle, A. Marchesoni, E.G. Favalli, R. Gorla, M. Filippini, R. Caporali, F. Bobbio-Pallavicini, C. Montecucco, F. Atzeni

290-295

https://doi.org/10.4081/reumatismo.2008.290

2073

PDF: 1081
Biologic therapy with anti-TNFa in rheumathoid atrhritis

G. Ferraccioli

17-21

https://doi.org/10.4081/reumatismo.2005.4s.17

758

PDF: 684
Neprhrotic syndrome in a patient with rheumatoid arthritis treated with adalimumab: a case report

M.G. Portuesi, P. Perosa

61-63

https://doi.org/10.4081/reumatismo.2008.61

1174

PDF: 886
Differences in pharmacology of tumor necrosis factor (TNF) antagonists

U. Fiocco, S. Bombardieri

8-16

https://doi.org/10.4081/reumatismo.2005.4s.8

1155

PDF: 1766
Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab

J. Finsterer

03-05-2022

https://doi.org/10.4081/reumatismo.2022.1474

1959

PDF: 515
Leishmaniasis in rheumatoid arthritis

C. Pizzorni, M.E. Secchi, M. Cutolo

235-239

https://doi.org/10.4081/reumatismo.2007.235

1504

PDF: 973
Effects of TNF antagonists on immune and neuroendocrine system

G. Valesini, M. Cutolo

3-7

https://doi.org/10.4081/reumatismo.2005.4s.3

1186

PDF: 779
COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?

Z. Ahmadinejad, R. Assari, N. Ayoobi Yazdi, S.-H. Mazloomi, P. Javanshayani, H. Khalili Afousi, V. Ziaee

173-177

19-11-2020

https://doi.org/10.4081/reumatismo.2020.1289

1635

PDF: 1014
A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens

Giovanna Cuomo, Gabriella Molinaro, Giovanni La Montagna, Sergio Migliaresi, Gabriele Valentini

22-25

https://doi.org/10.4081/reumatismo.2006.22

1535

PDF: 2014
Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects

C. Botsios, P. Ostuni, P. Sfriso, A. Furlan, U. Fiocco, D. Sgarabotto, S. Todesco

224-235

https://doi.org/10.4081/reumatismo.2003.224

1133

PDF: 2557
Safety of anti-TNFa biological drugs

F. Trotta, G. Valentini

34-39

https://doi.org/10.4081/reumatismo.2005.4s.34

1156

PDF: 1154
Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: a case report

V.F. Azevedo, C.F. Pietrovski, M. de Almeida Santos Jr

283-285

https://doi.org/10.4081/reumatismo.2010.283

1311

PDF: 1284

1 - 25 of 25 items

Search

Search Results

Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis

Splenic tuberculosis in a patient with ankylosing spondylitis treated with adalimumab

Anti-TNF agents for the treatment of active non-radiographic axial spondyloarthritis

Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs

A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes

Psoriatic arthritis: treatment strategies using biologic agents

Anti-tumor necrosis factor α: originators versus biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

A short history of anti-rheumatic therapy - VII. Biological agents

GISEA: an Italian biological agents registry in rheumatology

Approved indications and other possible utilizations of anti-TNFa biologic drugs

Inflammatory back pain as an unusual manifestation of Takayasu arteritis: a case report

Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

Biologic therapy with anti-TNFa in spondyloarthritides and other autoimmune diseases

Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN)

Biologic therapy with anti-TNFa in rheumathoid atrhritis

Neprhrotic syndrome in a patient with rheumatoid arthritis treated with adalimumab: a case report

Differences in pharmacology of tumor necrosis factor (TNF) antagonists

Herpes zoster seven days after SARS-CoV-2 vaccination in a patient with ankylosing spondylitis under adalimumab

Leishmaniasis in rheumatoid arthritis

Effects of TNF antagonists on immune and neuroendocrine system

COVID-19 pandemic and biological therapy in rheumatologic disorders: how to deal with?

A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens

Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects

Safety of anti-TNFa biological drugs

Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: a case report

authors

reviewers

Categories

indexing

Keywords